Month: January 2014

Palatin Technologies to Present at the 16th Congress of the European Society for Sexual Medicine

CRANBURY, N.J., Jan. 30, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that data from a 12-week placebo-controlled dose-ranging study using self-administered subcutaneous bremelanotide for the treatment of female sexual dysfunctions will be presented at the 16th Congress of the European Society for Sexual Medicine in Istanbul, Turkey on Friday, January 31, 2014 …

Palatin Technologies to Present at the 16th Congress of the European Society for Sexual Medicine Read More »

Palatin Technologies, Inc. Receives $1.85 Million from Sale of New Jersey State Tax Credits

CRANBURY, N.J., Jan. 23, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that it has received approximately $1.85 million of non-dilutive funding via the State of New Jersey’s Technology Business Tax Certificate Transfer …

Palatin Technologies, Inc. Receives $1.85 Million from Sale of New Jersey State Tax Credits Read More »

Palatin Technologies Responds to Unusual Market Activity

CRANBURY, N.J., Jan. 13, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) (the “Company”) announced today that in view of the unusual market activity in common stock of the Company on Monday, January 13, 2014, the NYSE MKT (the “Exchange”) has contacted the Company in accordance with the Exchange’s usual practice. The Company stated that …

Palatin Technologies Responds to Unusual Market Activity Read More »

Scroll to Top